Long-Term Benefit Observed With Sotorasib in KRAS-Mutant Non-Small Cell Lung Cancer
The 2-year overall survival rate was 32.5%.
All articles by Alan P. Lyss, MD
Eponyms in Oncology: Zollinger-Ellison Syndrome
This weekly series highlights eponyms in oncology. This week, we explore the history and namesakes of Zollinger-Ellison syndrome.
Recurrent DCIS Not Always Related to Primary Tumor
Researchers found that, in 18% of recurrences, the new tumor was molecularly unrelated to the original tumor.
Eponyms in Oncology: Li-Fraumeni Syndrome
This weekly series highlights eponyms in oncology. This week, we explore the history and namesakes of Li-Fraumeni syndrome.
Eponyms in Oncology: Lynch Syndrome
This weekly series highlights eponyms in oncology. This week, we explore the history and namesake of Lynch syndrome.
Eponyms in Oncology: HeLa Cells
This weekly series highlights eponyms in oncology. This week, we explore the history and namesake of HeLa cells.
Eponyms in Oncology: Waldenström Macroglobulinemia
This weekly series highlights eponyms in oncology. This week, we explore the history and namesake of Waldenström macroglobulinemia.
Findings Support Retesting for MMRD at Uterine Cancer Recurrence
Patients who have mismatch repair proficiency in the primary setting may have mismatch repair deficiency at recurrence.
Eponyms in Oncology: Virchow’s Node
This weekly series highlights eponyms in oncology. This week, we explore the history and namesake of Virchow’s node.
Eponyms in Oncology: Sister Mary Joseph Nodule
This weekly series highlights eponyms in oncology. This week, we explore the history and namesake of the Sister Mary Joseph nodule.
- Loading...
Loading...
Next post in General Oncology
Loading... 
Loading...